The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...

Study suggests CD4+ T cells mediate these immune-related toxicities ...

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.

Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...

Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...